Economic burden of psoriasis in the United States a systematic review

Elizabeth A. Brezinski, Jaskaran S. Dhillon, April W. Armstrong

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

IMPORTANCE: The total cost of psoriasis in the United States is unknown. Defining the US economic burden of psoriasis is needed because it provides the foundation for research, advocacy, and educational efforts. OBJECTIVE: To determine the US economic burden of psoriasis from a societal perspective. EVIDENCE REVIEW: PubMed and MEDLINE databases were searched between January 1, 2008, and September 20, 2013, for economic investigations on the direct, indirect, intangible, and comorbidity costs of adult psoriasis in the United States. The base year costs were adjusted to 2013 US dollars using the Consumer Price Index for All Urban Consumers and multiplied by the estimated number of US patients with psoriasis in 2013 to determine the 2013 psoriasis cost burden. FINDINGS: Among 100 identified articles, 22 studies were included in the systematic review. The direct psoriasis costs ranged from $51.7 billion to $63.2 billion, the indirect costs ranged from $23.9 billion to $35.4 billion, and medical comorbidities were estimated to contribute $36.4 billion annually in 2013 US dollars. Patients with psoriasis would pay a lifetime cost of $11 498 for relief of physical symptoms and emotional health; however, intangible cost data are limited. The annual US cost of psoriasis amounted to approximately $112 billion in 2013. CONCLUSIONS AND RELEVANCE: The economic burden of psoriasis is substantial and significant in the United States.

Original languageEnglish (US)
Pages (from-to)651-658
Number of pages8
JournalJAMA Dermatology
Volume151
Issue number6
DOIs
StatePublished - Jun 1 2015
Externally publishedYes

Fingerprint

Psoriasis
Economics
Costs and Cost Analysis
Comorbidity
PubMed
MEDLINE
Databases
Health

ASJC Scopus subject areas

  • Dermatology

Cite this

Economic burden of psoriasis in the United States a systematic review. / Brezinski, Elizabeth A.; Dhillon, Jaskaran S.; Armstrong, April W.

In: JAMA Dermatology, Vol. 151, No. 6, 01.06.2015, p. 651-658.

Research output: Contribution to journalArticle

Brezinski, Elizabeth A. ; Dhillon, Jaskaran S. ; Armstrong, April W. / Economic burden of psoriasis in the United States a systematic review. In: JAMA Dermatology. 2015 ; Vol. 151, No. 6. pp. 651-658.
@article{ecee50a39cb14f10a3efc2f70f7a8be7,
title = "Economic burden of psoriasis in the United States a systematic review",
abstract = "IMPORTANCE: The total cost of psoriasis in the United States is unknown. Defining the US economic burden of psoriasis is needed because it provides the foundation for research, advocacy, and educational efforts. OBJECTIVE: To determine the US economic burden of psoriasis from a societal perspective. EVIDENCE REVIEW: PubMed and MEDLINE databases were searched between January 1, 2008, and September 20, 2013, for economic investigations on the direct, indirect, intangible, and comorbidity costs of adult psoriasis in the United States. The base year costs were adjusted to 2013 US dollars using the Consumer Price Index for All Urban Consumers and multiplied by the estimated number of US patients with psoriasis in 2013 to determine the 2013 psoriasis cost burden. FINDINGS: Among 100 identified articles, 22 studies were included in the systematic review. The direct psoriasis costs ranged from $51.7 billion to $63.2 billion, the indirect costs ranged from $23.9 billion to $35.4 billion, and medical comorbidities were estimated to contribute $36.4 billion annually in 2013 US dollars. Patients with psoriasis would pay a lifetime cost of $11 498 for relief of physical symptoms and emotional health; however, intangible cost data are limited. The annual US cost of psoriasis amounted to approximately $112 billion in 2013. CONCLUSIONS AND RELEVANCE: The economic burden of psoriasis is substantial and significant in the United States.",
author = "Brezinski, {Elizabeth A.} and Dhillon, {Jaskaran S.} and Armstrong, {April W.}",
year = "2015",
month = "6",
day = "1",
doi = "10.1001/jamadermatol.2014.3593",
language = "English (US)",
volume = "151",
pages = "651--658",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - Economic burden of psoriasis in the United States a systematic review

AU - Brezinski, Elizabeth A.

AU - Dhillon, Jaskaran S.

AU - Armstrong, April W.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - IMPORTANCE: The total cost of psoriasis in the United States is unknown. Defining the US economic burden of psoriasis is needed because it provides the foundation for research, advocacy, and educational efforts. OBJECTIVE: To determine the US economic burden of psoriasis from a societal perspective. EVIDENCE REVIEW: PubMed and MEDLINE databases were searched between January 1, 2008, and September 20, 2013, for economic investigations on the direct, indirect, intangible, and comorbidity costs of adult psoriasis in the United States. The base year costs were adjusted to 2013 US dollars using the Consumer Price Index for All Urban Consumers and multiplied by the estimated number of US patients with psoriasis in 2013 to determine the 2013 psoriasis cost burden. FINDINGS: Among 100 identified articles, 22 studies were included in the systematic review. The direct psoriasis costs ranged from $51.7 billion to $63.2 billion, the indirect costs ranged from $23.9 billion to $35.4 billion, and medical comorbidities were estimated to contribute $36.4 billion annually in 2013 US dollars. Patients with psoriasis would pay a lifetime cost of $11 498 for relief of physical symptoms and emotional health; however, intangible cost data are limited. The annual US cost of psoriasis amounted to approximately $112 billion in 2013. CONCLUSIONS AND RELEVANCE: The economic burden of psoriasis is substantial and significant in the United States.

AB - IMPORTANCE: The total cost of psoriasis in the United States is unknown. Defining the US economic burden of psoriasis is needed because it provides the foundation for research, advocacy, and educational efforts. OBJECTIVE: To determine the US economic burden of psoriasis from a societal perspective. EVIDENCE REVIEW: PubMed and MEDLINE databases were searched between January 1, 2008, and September 20, 2013, for economic investigations on the direct, indirect, intangible, and comorbidity costs of adult psoriasis in the United States. The base year costs were adjusted to 2013 US dollars using the Consumer Price Index for All Urban Consumers and multiplied by the estimated number of US patients with psoriasis in 2013 to determine the 2013 psoriasis cost burden. FINDINGS: Among 100 identified articles, 22 studies were included in the systematic review. The direct psoriasis costs ranged from $51.7 billion to $63.2 billion, the indirect costs ranged from $23.9 billion to $35.4 billion, and medical comorbidities were estimated to contribute $36.4 billion annually in 2013 US dollars. Patients with psoriasis would pay a lifetime cost of $11 498 for relief of physical symptoms and emotional health; however, intangible cost data are limited. The annual US cost of psoriasis amounted to approximately $112 billion in 2013. CONCLUSIONS AND RELEVANCE: The economic burden of psoriasis is substantial and significant in the United States.

UR - http://www.scopus.com/inward/record.url?scp=84931090028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931090028&partnerID=8YFLogxK

U2 - 10.1001/jamadermatol.2014.3593

DO - 10.1001/jamadermatol.2014.3593

M3 - Article

C2 - 25565304

AN - SCOPUS:84931090028

VL - 151

SP - 651

EP - 658

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 6

ER -